An interesting example is a recent analysis demonstrating that cancer patients with a homozygote HLA-A*03 haplotype had shorter survival after receiving immune checkpoint inhibitor therapy than heterozygous HLA-A*03 patients and patients without this allele [16]. This evidence concerns the gene HLA-A and cancer.